|
**Overview**: Carrier Screening 420 Genes Panel**Introduction**: The Carrier Screening 420 Genes Panel is a diagnostic tool designed to screen for genetic carrier status using whole blood samples. In India, carrier screening is crucial for autosomal recessive disorders (e.g., thalassemia, sickle cell, cystic fibrosis, SMA) prevalent in consanguineous marriages (prevalence 5-10 percent in certain communities), with expanded panels detecting 420 genes for comprehensive risk assessment. High burden of genetic disorders from under-screening in rural/low-SES populations, limited genetic counseling, delayed preconception testing leading to affected offspring. Per molecular pathology practices aligned with ICMR and Indian Society of Human Genetics guidelines, the test employs NGS for mutation analysis over 1-2 days with high sensitivity/specificity, valuable for preconception/prenatal counseling. This diagnostic falls under genetic screening and targets couples planning pregnancy, addressing accurate detection to guide reproductive decisions. With elevated morbidity due to under-screening, the test supports public health efforts by enabling precise risk identification and reducing genetic disease burden. Its whole blood-based approach ensures reliable detection.**Other Names**: Carrier 420 Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology, compliant with 2025 standards.**Historical Milestone**: Expanded NGS panels; in India, growing in genetic counseling centers.**Purpose**: The test screens for 1 parameter (420 gene mutation analysis) to guide carrier status assessment, identify recessive risks, inform counseling.**Test Parameters**: 1. 420 Gene Mutation Analysis.**Pretest Condition**: No fasting required; patients should report family history of genetic disorders or consanguinity.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for NGS).**Medical History**: Patients should provide details on family genetic disorders, consanguinity, ethnicity.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of carrier status including affected offspring, benefits of screening, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using NGS by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive carrier status indicates reproductive risk, necessitating genetic counseling. Negative may require follow-up if family history strong.**Specialist Consultation**: Genetic counselors should be consulted for interpretation.**Additional Supporting Tests**: Partner screening for confirmation.**Test Limitations**: Covers selected genes; comprehensive approach required.**References**: Indian Journal of Medical Genetics 2024, Carrier Screening Studies India 2023. |
